Carla Bartosch

Instituto Português de Oncologia Francisco Gentil

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Manuel R. Teixeira

Instituto Português de Oncologia Francisco Gentil

José Manuel Lopes

Universidade do Porto

Cármen Jerónimo

IPO Porto

Carla Pinto

University of Trás-os-Montes and Alto Douro

Miguel Henriques Abreu

IPO Porto

Alexandra Matias

Hospital de São João

Joana Patrícia Rodrigues Félix Peixoto de Almeida

Hospital Pedro Hispano

Ana Peixoto

Instituto Português de Oncologia Francisco Gentil

Pedro Pinto

Instituto Português de Oncologia Francisco Gentil

Manuela Pinheiro

Instituto Português de Oncologia Francisco Gentil

Cooperative Institutions

Universidade do Porto

128

IPO Porto

100

Instituto Português de Oncologia Francisco Gentil

Hospital de São João

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto

Centro Hospitalar do Porto

Centro Hospitalar de Vila Nova de Gaia

University of Coimbra

Instituto Português de Oncologia de Coimbra Francisco Gentil

Institute of Biomedical Science

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors

PLoS ONE (2015)

Carla Bartosch Sara Monteiro‐Reis Renata Vieira Armindo Pereira Marta Rodrigues

Patients with endometrial endometrioid carcinoma (EEC) that present with advanced primary disease and develop recurrences have a poor outcome. The phenotype of EEC metastases and recurrences is poorly studied. We evaluated the morphological features and ER-alpha/PRA/p53 immunohistochemical expression of a sample of 45 EEC metastases compared to matched primary tumors. Additionally, we studied methylation levels of ER-alpha/PRA gene promoters. The distribution of histological FIGO grade was significantly different in metastases, which disclosed higher grade than primary tumors (p = 0.005). Mitotic index was significantly lower in metastases compared to matched primary tumors (p<0.001). ER-alpha (p = 0.002) and PRA (p<0.001) median H-scores were significantly lower in metastases than in matched primary EECs, but there was no significant difference concerning p53 expression (p = 0.056). ER-alpha/PRA expression differences did not correlate with differences in metastases morphology. ER-alpha/PRA gene promoter levels were globally low (range: 0% to 11.9%). One case showed higher ER-alpha gene promoter methylation in metastasis compared to matched EEC primary tumor. Regarding PRA, there was a significant higher frequency of its promotor methylation in metastases compared to primary tumors (51.6% vs. 22.7%, p = 0.022). In conclusion, EEC metastatic disease displays phenotypic changes along with ER-alpha and PRA decreased expression compared to primary tumors. ER-alpha and PRA gene promoter methylation seems to play a limited role in the etiology of these alterations. PR expression assessment for hormonal treatment decision of patients with advanced tumors, may be more adequate in metastases than in EEC primary tumors.

Primary tumor

Alpha (finance)

10.1371/journal.pone.0134969

Cite

Citations (40)

Short tandem repeat analysis: a practical tool to identify specimen mix-ups in the pathology laboratory

Virchows Archiv (2023)

David João Sara Cardoso Paula Monteiro Conceição Leal Carla Bartosch

Anatomical pathology

Lobular carcinoma

Vaginal smear

10.1007/s00428-023-03578-7

Cite

Citations (0)

Reproducibility of measurement of myometrial invasion in endometrial carcinoma

Virchows Archiv (2016)

Louis J.M. van der Putten Koen Van de Vijver Carla Bartosch Ben Davidson Sónia Gatius

Myometrial invasion (MI) as a percentage (%MI), categorized into <50 or ≥50 %, is an important predictor of prognosis in endometrial carcinoma. Recent studies suggest that tumor-free distance (TFD) to serosa and the absolute depth of invasion (DOI) might be stronger predictors of prognosis. Although reproducibility is important in clinical practice for patient prognostication and treatment, reproducibility of these methods for the measurement of MI is largely unknown. One or two slides from 50 patients with FIGO stage I endometrioid endometrial carcinoma were viewed by seven gynecological pathologists, who were requested to measure %MI, TFD, and DOI. We categorized %MI as <50 % (including no MI) or ≥50 %, TFD as ≤1.75 or >1.75 mm (including no MI), ≤7 or >7 mm (including no MI), and ≤10 or >10 mm (including no MI) and DOI as <4 mm (including no MI) or ≥4 mm. Light's kappa for multi-rater agreement was calculated. The %MI, TFD, and DOI could be measured in 88, 83, and 79 % of cases, respectively. Kappa was 0.75 for %MI, 0.77, 0.73, and 0.69 respectively for TFD with cutoffs of 1.75, 7, and 10 mm, and 0.59 for DOI. Pathologists reach substantial agreement when measuring %MI and TFD and moderate agreement when measuring DOI. The %MI can be measured in more cases than TFD and DOI. This supports the use of %MI in daily clinical practice, but future studies should compare %MI and TFD more extensively, including inter-observer variability.

Kappa

10.1007/s00428-016-2035-5

Cite

Citations (14)

Small fallopian tube carcinoma with extensive upper abdominal dissemination: a case report

Journal of Medical Case Reports (2013)

Carolina Oliveira Hálio Duarte Carla Bartosch Daniel Pinheiro Fernandes

Fallopian tube carcinoma is a rare gynecological malignancy with low accuracy detection preoperatively. The symptoms are unspecific and imaging can be misleading. Since it was first described in 1847, there have been only a little over 2000 case reports.This case report describes a 66-year-old Caucasian woman who presented with progressive diffuse abdominal pain, without other symptoms. After abdominopelvic magnetic resonance imaging, she was sent to the Portuguese Oncology Institute of Oporto with the suspicion of peritoneal carcinomatosis of unknown primary tumor. Due to a pelvic palpable mass (calcified giant uterine fibroid) she was directed to the Gynecology team. Surgery was performed and a large mass in her upper abdomen was identified. The extemporary examination revealed a high-grade adenocarcinoma. During surgery a small change of color and consistency of her left fallopian tube was noted and unilateral adnexectomy was performed. After pathologic and immunohistochemistry tests, the diagnosis of fallopian tube carcinoma with peritoneal dissemination was made.This case is very unique in the way that a small primary fallopian tube carcinoma was able to disseminate to the upper abdominal quadrant with little pelvic dissemination. The symptoms and imaging were unspecific. Although a rare occurrence, we should not forget fallopian tube carcinoma in the differential diagnosis of peritoneal carcinomatosis, even in the absence of Latzke's triad.

Fallopian tube

Gynecologic oncology

Fallopian tube cancer

Quadrant (abdomen)

10.1186/1752-1947-7-252

Cite

Citations (9)

Phenotypic Intratumoral Heterogeneity of Endometrial Carcinomas

International Journal of Gynecological Pathology (2017)

Cátia Silva A. Luís Eduardo Rocha Carla Bartosch José Manuel Lopes

Intratumoral heterogeneity has been shown to play an important role in diagnostic accuracy, development of treatment resistance, and prognosis of cancer patients. Recent studies have proposed quantitative measurement of phenotypic intratumoral heterogeneity, but no study is yet available in endometrial carcinomas. In our study we evaluated the phenotypic intratumoral heterogeneity of a consecutive series of 10 endometrial carcinomas using measures of dispersion and diversity. Morphometric architectural (%tumor cells, %solid tumor, %differentiated tumor, and %lumens) and nuclear [volume-weighted mean nuclear volume ((Equation is included in full-text article.))] parameters, as well as estrogen receptor, progesterone receptor, p53, vimentin, and beta-catenin immunoexpression (H-score) were digitally analyzed in 20 microscopic fields per carcinoma. Quantitative measures of intratumoral heterogeneity included coefficient of variation (CV) and relative quadratic entropy (rQE). In each endometrial carcinoma there was slight variation of architecture from field to field, resulting in globally low levels of heterogeneity measures (mean CV %tumor cells: 0.10, %solid tumor: 0.73, %differentiated tumor: 0.19, %lumens: 0.61 and mean rQE %tumor cells: 18.5, %solid tumor: 20.3, %differentiated tumor: 25.6, %lumens: 21.8). Nuclear intratumoral heterogeneity was also globally low (mean (Equation is included in full-text article.)CV: 0.23 and rQE: 27.3), but significantly higher than the heterogeneity of architectural parameters within most carcinomas. In general, there was low to moderate variability of immunoexpression markers within each carcinoma, but estrogen receptor (mean CV: 0.56 and rQE: 46.2) and progesterone receptor (mean CV: 0.60 and rQE: 39.3) displayed the highest values of heterogeneity measures. Intratumoral heterogeneity of immunoexpression was significantly higher than that observed for morphometric parameters. In conclusion, our study indicates that endometrial carcinomas present a variable but predominantly low degree of phenotypic intratumoral heterogeneity.

Progesterone receptor

10.1097/pgp.0000000000000400

Cite

Citations (3)

Endometrial endometrioid adenocarcinoma associated with primitive neuroectodermal tumour of the uterus: a poor prognostic subtype of uterine tumours

Medical Oncology (2010)

Carla Bartosch Joana Vieira Manuel R. Teixeira José Manuel Lopes

Primitive neuroectodermal tumor

Vaginal bleeding

10.1007/s12032-010-9579-z

Cite

Citations (6)

Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation

Gynecologic Oncology Reports (2022)

Bárbara Lima Miguel Henriques Abreu Susana Sousa Carla Bartosch Deolinda Pereira

Low-grade serous ovarian cancer (LGSOC) is now considered a different entity from high-grade serous ovarian cancer. The chemoresistance inherent to this type of ovarian cancer narrows the therapeutic options, especially in the recurrent setting. It is thought that the mitogen-activated protein kinase (MAPK) pathway plays a significant role in the pathogenesis of these tumours, and about 2 to 20% of LGSOC harbour a BRAF mutation. Here we present a case report of two patients with a BRAF V600E mutation that achieved sustained clinical responses with combination treatment with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor).

Trametinib

Dabrafenib

V600E

Serous ovarian cancer

10.1016/j.gore.2022.100942

Cite

Citations (9)

Recycling the Purpose of Old Drugs to Treat Ovarian Cancer

International Journal of Molecular Sciences (2020)

Mariana Nunes Miguel Henriques Abreu Carla Bartosch Sara Ricardo

The main challenge in ovarian cancer treatment is the management of recurrences. Facing this scenario, therapy selection is based on multiple factors to define the best treatment sequence. Target therapies, such as bevacizumab and polymerase (PARP) inhibitors, improved patient survival. However, despite their achievements, ovarian cancer survival remains poor; these therapeutic options are highly costly and can be associated with potential side effects. Recently, it has been shown that the combination of repurposed, conventional, chemotherapeutic drugs could be an alternative, presenting good patient outcomes with few side effects and low costs for healthcare institutions. The main aim of this review is to strengthen the importance of repurposed drugs as therapeutic alternatives, and to propose an in vitro model to assess the therapeutic value. Herein, we compiled the current knowledge on the most promising non-oncological drugs for ovarian cancer treatment, focusing on statins, metformin, bisphosphonates, ivermectin, itraconazole, and ritonavir. We discuss the primary drug use, anticancer mechanisms, and applicability in ovarian cancer. Finally, we propose the use of these therapies to perform drug efficacy tests in ovarian cancer ex vivo cultures. This personalized testing approach could be crucial to validate the existing evidences supporting the use of repurposed drugs for ovarian cancer treatment.

Drug repositioning

Taxane

10.3390/ijms21207768

Cite

Citations (25)

Cellular dynamics of cervical remodelling: insights from preterm and term labour

Archives of Gynecology and Obstetrics (2025)

Joana Patrícia Rodrigues Félix Peixoto de Almeida Alexandra Matias Carla Bartosch

Preterm labour

Dynamics

10.1007/s00404-024-07902-7

Cite